Showing results (141-150 of 166) with videos related to
Sort By:
Pageof 17
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 24, 2012
Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM studyMichael A Bolognese, Christence Stubbe Teglbjærg, Jose R Zanchetta, et al.The Journal of Rheumatology|April 4, 2006
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extensionAndreas Reiff, Daniel J Lovell, Janet Van Adelsberg, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 29, 2014
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonateJ P Brown, C Roux, P R Ho, et al.Lancet (London, England)|November 23, 2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonChristopher P Cannon, Sean P Curtis, Garret A FitzGerald, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 3, 2014
Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extensionJacques P Brown, Ian R Reid, Rachel B Wagman, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 9, 2014
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral densityRobert R Recker, Charles T Benson, Toshio Matsumoto, et al.Obstetrics and Gynecology|July 2, 2013
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trialChris Recknor, Edward Czerwinski, Henry G Bone, et al.The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 17, 2005
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronateJean-Yves Reginster, Dieter Felsenberg, Cyrus Cooper, et al.Pageof 17